Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis
In preclinical studies, avenciguat shows the potential to influence vascular, fibrotic and immune-related processes in murine models of SSc. These studies suggest that it may offer therapeutic benefit across multiple aspects of SSc pathophysiology and support the rationale for further investigation in a Phase II clinical trial (VITALISScE™; NCT05559580) of avenciguat in SSc.
Authors
- Gerald Nabozny (ORCID: https://orcid.org/0000-0002-8679-7078)
- David L. Ebenezer (ORCID: https://orcid.org/0000-0001-7915-1159)
- Jörg H. W. Distler (ORCID: https://orcid.org/0000-0001-7408-9333)
- Christian T. Wohnhaas (ORCID: https://orcid.org/0000-0002-1450-9284)
- Chao-Ting Wang
- Christoph Liebel
- Thuong Trinh‐Minh (ORCID: https://orcid.org/0009-0008-3345-3694)
- Julia Kaufman
- Cuong Tran Manh (ORCID: https://orcid.org/0000-0001-6630-9201)
- Denis Delić (ORCID: https://orcid.org/0000-0003-0233-8374)
- Lee-Anne Daley
- Xiang Zhou (ORCID: https://orcid.org/0000-0003-1082-2027)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Fudan University (CN)
- Düsseldorf University Hospital (DE)
- Boehringer Ingelheim (France) (FR)
- Boehringer Ingelheim (United States) (US)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1093/rheumatology/keaf109
- Citations
- 6
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 9.11